









Markets
/
Stocks
/
nasdaq-incr
/

InterCure Ltd

INCR



View Detailed Chart

1.391USD

-0.069-4.70%

Market hours （ET）Quotes delayed by 15 min

63.41MMarket Cap

3.03P/E TTM



InterCure Ltd

1.391

-0.069-4.70%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

Intraday

30m

Today

-4.70%

5 Days

-5.35%

1 Month

-14.11%

6 Months

-13.04%

Year to Date

-12.49%

1 Year

-20.26%

View Detailed Chart

TradingKey Stock Score of InterCure Ltd

Currency: USD Updated: 2025-11-03

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Despite a weak stock market performance, the company shows strong technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

InterCure Ltd's Score

Industry at a Glance

Industry Ranking

65 / 78

Overall Ranking

478 / 4617

Industry

Healthcare Providers & Services

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

InterCure Ltd Highlights

StrengthsRisks

InterCure Ltd is an Israel-based company primarily enagged in cannabis industry. Thorugh its wholly owned subsidiary Canndoc the Company operates as licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products.

Fairly Valued

The company’s latest PE is 0.00, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 2.52M shares, decreasing 20.52% quarter-over-quarter.